Simulations Plus, Inc.: insider trades · United States · SEC (Form 4)

About Simulations Plus, Inc.

Simulations Plus, Inc. (NASDAQ: SLP) is a U.S.-based specialist in modeling and simulation software and scientific consulting for the pharmaceutical and biotechnology industries. Listed on the U.S. NASDAQ market, the company is headquartered in Lancaster, California, United States. It was founded in 1996 and has evolved into a recognized provider of decision-support tools used in drug discovery, development, and optimization. ([fintel.io](https://fintel.io/doc/sec-simulations-plus-inc-1023459-10k-2024-october-30-20026-896?utm_source=openai)) The business model is built on two main pillars: software and consulting services. On the software side, Simulations Plus markets best-known products such as GastroPlus, a widely used platform for simulating absorption, pharmacokinetics, and pharmacodynamics, along with additional tools for simulation and molecular-property prediction. The company also emphasizes capabilities in cheminformatics, biosimulation, simulation-enabled intelligence, clinical operations technology, and medical communications. ([stockanalysis.com](https://stockanalysis.com/stocks/slp/company/?utm_source=openai)) Its competitive position comes from a fairly uncommon combination: an established scientific software base, regulatory and domain expertise, and consulting services that support pharmaceutical clients across the development lifecycle. In a market where faster development, lower R&D costs, and better trial efficiency are increasingly important, this offering addresses a structural need. The company serves an international customer base, and its annual reporting has referenced independent distributors in Japan, China, India, South Korea, and Brazil, underscoring a commercial footprint beyond North America. ([fintel.io](https://fintel.io/doc/sec-simulations-plus-inc-1023459-10k-2024-october-30-20026-896?utm_source=openai)) Recent milestones highlight the company’s continued relevance for investors following specialized healthcare software names. In 2025, Simulations Plus released quarterly earnings updates and guidance revisions, keeping the stock on the radar of investors looking at niche healthcare technology and small-cap software companies. Management also described the company as a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications, while providing fiscal 2026 outlook commentary. In addition, Simulations Plus announced an investment in Nurocor, a clinical development technology company, suggesting a strategy to broaden its solution ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1023459/000102345925000051/pressrelease10222025.htm?utm_source=openai)) For French-speaking investors, Simulations Plus is best viewed as a specialized science-and-software name with exposure to global pharma innovation, a clear U.S. NASDAQ listing, and a differentiated niche positioning supported by recurring client relationships and mission-critical tools.